EBS
Quality Rating
Emergent BioSolutions Inc. (EBS) specializes in biopharmaceutical solutions for public health threats, including biodefense vaccines. The company fails key financial screening criteria due to excessive debt (151.32% of market cap) and liquidity ratios (33.89%), exceeding thresholds across AAOIFI, MSCI, and S&P standards. Business activities are primarily compliant in healthcare but non-compliant in biodefense segments, contributing to overall non-compliance. No inclusion in major Shariah indices confirms exclusion. Purification is required for minor interest income, with a quality rating reflecting strong income compliance but critical financial and activity concerns.
Purification Required
Moderate purification required - consider carefully
Index Inclusion
Not included in any major Shariah indices (S&P, MSCI, FTSE, DJIM)
Key Compliance Considerations
- Debt Ratio: 151.32% (exceeds 30-33% thresholds)
- Liquidity Ratio: 33.89% (exceeds 30-33% thresholds)
- Biodefense activities (40% revenue) deemed non-compliant by strict standards
Debt Ratio
151.3%
Liquidity Ratio
33.9%
Interest Income Ratio
2.3%
Purification
2.33%